Tuesday, September 22, 2026

Travere Therapeutics plans CEO transition for December 2026

Travere Therapeutics has announced a planned leadership change. Eric Dube, Ph.D., intends to step down as president and chief executive officer in December 2026, with the company citing his decision to focus more on his health and family.

The board has appointed Bradley L. Campbell as his successor. Campbell is expected to become president and CEO on December 1, 2026, and to join the company’s board of directors. Dube will remain in his current role until then and is scheduled to stay with Travere as an executive advisor through February 15, 2027, to support the transition.

Rare disease executive to take over

Campbell brings experience from the rare disease sector. He previously served as president and CEO of Amicus Therapeutics, which is now a wholly owned subsidiary of BioMarin Pharmaceutical. During almost 20 years at Amicus, he held positions of increasing responsibility and became CEO in 2022. Earlier in his career, he worked in commercial and business development roles at Genzyme and Bristol-Myers Squibb.

Travere pointed to Campbell’s background in developing and commercializing therapies for rare diseases, as well as his experience in scaling global rare disease operations. He also serves on boards and advisory bodies, including the Advisory Board of the Duke-Margolis Institute for Health Policy.

Dube has led Travere since 2019

Dube became president and CEO in January 2019. During his tenure, Travere secured regulatory approvals in IgA nephropathy and focal segmental glomerulosclerosis, or FSGS. The company presents itself as a biopharmaceutical business focused on rare diseases, with a particular emphasis on rare kidney conditions.

The company also credits Dube with expanding its pipeline and strengthening its organizational capabilities. Travere referred to progress around FILSPARI, including activity in FSGS and ongoing commercialization in IgA nephropathy.

Board plans orderly handover

According to Travere, the board worked with Dube on succession planning before selecting Campbell. The company said the process focused on the capabilities needed for the next stage of its development.

The transition comes as Travere continues to advance its commercial products and clinical pipeline. In its announcement, the company also highlighted standard biopharmaceutical risks, including regulatory review, clinical trial execution, market access, reimbursement, manufacturing and financing.